Literature DB >> 18332167

Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.

David L Wyles1, Kelly A Kaihara, Robert T Schooley.   

Abstract

Rapid emergence of resistance to monotherapy with virus-specific inhibitors necessitates combination therapy. ACH-806 is a hepatitis C virus NS4A inhibitor with a novel mechanism of action and resistance pathway. This compound was synergistic with NS3 protease inhibitors and NS5B nucleoside and nonnucleoside polymerase inhibitors.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18332167      PMCID： PMC2346627          DOI： 10.1128/AAC.01208-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Effect of alpha interferon on the hepatitis C virus replicon.

Authors:  J T Guo; V V Bichko; C Seeger
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties.

Authors:  David B Olsen; Anne B Eldrup; Linda Bartholomew; Balkrishen Bhat; Michele R Bosserman; Alessandra Ceccacci; Lawrence F Colwell; John F Fay; Osvaldo A Flores; Krista L Getty; Jay A Grobler; Robert L LaFemina; Eric J Markel; Giovanni Migliaccio; Marija Prhavc; Mark W Stahlhut; Joanne E Tomassini; Malcolm MacCoss; Daria J Hazuda; Steven S Carroll
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

3.  Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.

Authors:  Anne B Eldrup; Marija Prhavc; Jennifer Brooks; Balkrishen Bhat; Thazha P Prakash; Quanlai Song; Sanjib Bera; Neelima Bhat; Prasad Dande; P Dan Cook; C Frank Bennett; Steven S Carroll; Richard G Ball; Michele Bosserman; Christine Burlein; Lawrence F Colwell; John F Fay; Osvaldo A Flores; Krista Getty; Robert L LaFemina; Joseph Leone; Malcolm MacCoss; Daniel R McMasters; Joanne E Tomassini; Derek Von Langen; Bohdan Wolanski; David B Olsen
Journal:  J Med Chem       Date:  2004-10-07       Impact factor: 7.446

4.  An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.

Authors:  Daniel Lamarre; Paul C Anderson; Murray Bailey; Pierre Beaulieu; Gordon Bolger; Pierre Bonneau; Michael Bös; Dale R Cameron; Mireille Cartier; Michael G Cordingley; Anne-Marie Faucher; Nathalie Goudreau; Stephen H Kawai; George Kukolj; Lisette Lagacé; Steven R LaPlante; Hans Narjes; Marc-André Poupart; Jean Rancourt; Roel E Sentjens; Roger St George; Bruno Simoneau; Gerhard Steinmann; Diane Thibeault; Youla S Tsantrizos; Steven M Weldon; Chan-Loi Yong; Montse Llinàs-Brunet
Journal:  Nature       Date:  2003-10-26       Impact factor: 49.962

5.  Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor.

Authors:  Tammy T Nguyen; Adam T Gates; Lester L Gutshall; Victor K Johnston; Baohua Gu; Kevin J Duffy; Robert T Sarisky
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

6.  Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro.

Authors:  Giovanni Migliaccio; Joanne E Tomassini; Steven S Carroll; Licia Tomei; Sergio Altamura; Balkrishen Bhat; Linda Bartholomew; Michele R Bosserman; Alessandra Ceccacci; Lawrence F Colwell; Riccardo Cortese; Raffaele De Francesco; Anne B Eldrup; Krista L Getty; Xiaoli S Hou; Robert L LaFemina; Steven W Ludmerer; Malcolm MacCoss; Daniel R McMasters; Mark W Stahlhut; David B Olsen; Daria J Hazuda; Osvaldo A Flores
Journal:  J Biol Chem       Date:  2003-09-08       Impact factor: 5.157

7.  3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication.

Authors:  Christian Grünberger; David L Wyles; Kelly A Kaihara; Robert T Schooley
Journal:  J Infect Dis       Date:  2008-01-01       Impact factor: 5.226

8.  Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A protease.

Authors:  David M Andrews; Michael C Barnes; Mike D Dowle; S Lucy Hind; Martin R Johnson; Paul S Jones; Gail Mills; Angela Patikis; Tony J Pateman; Tracy J Redfern; J Ed Robinson; Martin J Slater; Naimisha Trivedi
Journal:  Org Lett       Date:  2003-11-27       Impact factor: 6.005

9.  Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.

Authors:  Yoko Tanabe; Naoya Sakamoto; Nobuyuki Enomoto; Masayuki Kurosaki; Eri Ueda; Shinya Maekawa; Tsuyoshi Yamashiro; Mina Nakagawa; Cheng-Hsin Chen; Nobuhiko Kanazawa; Sei Kakinuma; Mamoru Watanabe
Journal:  J Infect Dis       Date:  2004-03-16       Impact factor: 5.226

10.  Identification of N,N-disubstituted phenylalanines as a novel class of inhibitors of hepatitis C NS5B polymerase.

Authors:  Laval Chan; T Jagadeeswar Reddy; Mélanie Proulx; Sanjoy K Das; Oswy Pereira; Wuyi Wang; Arshad Siddiqui; Constantin G Yannopoulos; Carl Poisson; Nathalie Turcotte; Alexandre Drouin; M Hicham Alaoui-Ismaili; Richard Bethell; Martine Hamel; Lucille L'Heureux; Darius Bilimoria; Nghe Nguyen-Ba
Journal:  J Med Chem       Date:  2003-04-10       Impact factor: 7.446
View more
  13 in total

1.  Structural and functional parameters of the flaviviral protease: a promising antiviral drug target.

Authors:  Sergey A Shiryaev; Alex Y Strongin
Journal:  Future Virol       Date:  2010-09-01       Impact factor: 1.831

2.  Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals.

Authors:  Haihong Zhu; Flossie Wong-Staal; Haekyung Lee; Andrew Syder; Jeffrey McKelvy; Robert T Schooley; David L Wyles
Journal:  J Infect Dis       Date:  2012-02-15       Impact factor: 5.226

3.  Hepatitis C virus replication and potential targets for direct-acting agents.

Authors:  Jacqueline G O'Leary; Gary L Davis
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

4.  Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor.

Authors:  Libin Rong; Ruy M Ribeiro; Alan S Perelson
Journal:  Bull Math Biol       Date:  2012-05-26       Impact factor: 1.758

5.  MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.

Authors:  Nigel J Liverton; Steven S Carroll; Jillian Dimuzio; Christine Fandozzi; Donald J Graham; Daria Hazuda; M Katherine Holloway; Steven W Ludmerer; John A McCauley; Charles J McIntyre; David B Olsen; Michael T Rudd; Mark Stahlhut; Joseph P Vacca
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

6.  Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.

Authors:  Judith M Gottwein; Sanne B Jensen; Stéphanie B N Serre; Lubna Ghanem; Troels K H Scheel; Tanja B Jensen; Henrik Krarup; Nathalie Uzcategui; Lotte S Mikkelsen; Jens Bukh
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

7.  Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor.

Authors:  Hui-Mei Lin; Jing-Chyi Wang; Han-Shu Hu; Pei-Shan Wu; Chi-Chen Yang; Chung-Pu Wu; Szu-Yuan Pu; Tsu-An Hsu; Weir-Torn Jiaang; Yu-Sheng Chao; Jyh-Haur Chern; Teng-Kuang Yeh; Andrew Yueh
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

8.  Design, synthesis, characterization, and biological evaluation of nicotinoyl thioureas as antimicrobial and antioxidant agents.

Authors:  Bünyamin Özgeriş
Journal:  J Antibiot (Tokyo)       Date:  2021-01-14       Impact factor: 2.649

9.  Antiviral therapy for hepatitis C virus: beyond the standard of care.

Authors:  Leen Delang; Lotte Coelmont; Johan Neyts
Journal:  Viruses       Date:  2010-03-29       Impact factor: 5.818

10.  Modeling Suggests a Mechanism of Synergy Between Hepatitis C Virus Entry Inhibitors and Drugs of Other Classes.

Authors:  P Padmanabhan; N M Dixit
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.